🎉 Conference Highlights Published! The inaugural FASEB Science Research Conference (SRC) on Cellular Plasticity in Cancer—held in Hong Kong (May 2025)—is now featured in CHP Journal! Leading experts share how cancer cell plasticity drives heterogeneity, stemness & therapy

🔥 Hot off the press in CHP! “Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates” by Ashley A. Duhon, MD, PhD (@ashleyaduhon) & Karen McLean, MD, PhD (@karenmcl13) from @RoswellPark. ADCs are reshaping solid tumor therapy—but

This review from Drs. Duhon and McLean dissects how tumor heterogeneity—spatial, temporal, and microenvironmental—impacts the efficacy and resistance of antibody-drug conjugates (ADCs). Key insights: 🔹 7 FDA-approved ADCs now in solid tumors 🔹 Targeting strategies evolving

🔥 Just published in CHP! “Regulation of Cancer Stem Cells in the Tumor Microenvironment” A comprehensive review by Aidan Li, Na Li, Yajing Yang, Linzhou Wang, Jessica Miao & Qi-En Wang (Ohio State Univ, Colleage of Medicine, Dpet of Radiation Oncology @OhioStateMed; OSU

Continuing highlights from Li et al. (2025) — Figures 5–6 show: 📦 Exosome-mediated CSC–TME signaling 🌫️ Hypoxia + endothelial signals → Notch, Wnt, STAT3 activation & stemness marker upregulation

Key highlights from Li et al. (2025): CSC–TME networking drives progression & therapy resistance. 🔹 CSCs recruit & polarize TAMs & MDSCs 🔹 CAFs & MSCs reinforce stemness & EMT 🔹 Exosomes deliver pro-tumoral cargo 🔹 Endothelial cells + hypoxia fuel plasticity 🔹

🔥 New in CHP! “Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response” By Erik S. Knudsen, Thomas N. O’Connor & Agnieszka K. Witkiewicz @RoswellPark Cancer cells bend cell-cycle rules—switching CDK/Cyclin drivers to thrive & resist

✨ Spotlight review in CHP! Astrocyte plasticity shapes brain metastasis progression through tumor–astrocyte crosstalk By Rupleen Kaur (@rupleenkaur), Dr. Andrew Dhawan (@andrewdhawan) from @cwru & @ClevelandClinic, and Nalin Gupta (@WashUBME). OA Review:

✨ Spotlight review in CHP! DIAPH3: A Cytoskeleton Remodeler Driving Cancer Progression & a Potential Therapeutic Target By Jiangling Xiong & Lanxin Hu (co-first authors), with Prof. Dingxiao Zhang & team (Hunan Univ @hunanuniv), Prof. Yang Mei (Hunan Univ), Prof. Dinglan Wu

📈 Clinical & translational insights: F5: Prognostic impact—high DIAPH3 linked to poor survival T1: Roles across cancers (oncogenic, context-specific) T2: Small-molecule modulators (e.g., SMIFH2 inhibitor, IMM-01/02 agonists)

Still better than the NCI payline!

Finally out today in https://t.co/ixg7cjQ8Pw 3D chromatin reorganization in prostate cancer lineage transformation, critically regulated by Nkx2-1 transcriptional network.

Highlights from the review: 🧬 TERT, TP53/RB1, and chromatin modifiers in NEBC 🔁 Cellular plasticity: UC-to-NEBC transitions 🎯 Emerging targets: MET inhibitors, ADC-DLL3 ⬇️ Figures 1 & 2, Table 1 (🧵 ALT text provided for accessibility)

Fresh from the oven!! Our latest review published in @CHP_journal on the origin of PDAC CSCs and their inner and outer determinants by @diegonavarrove1 and myself. A little bit of inflammation, a little bit of CIN, tons of stemness!! Enjoy!! https://t.co/G1w7yAEC23

This powerhouse review traces the journey of #PancreaticCancer stem cells from origin to evolution. 🧬 CSCs aren’t fixed identities — they emerge dynamically via: • Acinar/ductal plasticity • KRAS/TP53-driven genomic instability • Tumor & host-derived inflammatory cues •

🔥 Hot off the press in @CHP_journal! A deep dive into how inner (KRAS/TP53, CIN) and outer (TME, inflammation) forces shape PDAC stemness & plasticity. Congrats @JuanCarlosLpz13 @diegonavarrove1 on this beautiful review! 🧬 https://t.co/TqoCoPzAux #PDAC #CancerStemCells

🔍 Visual Highlights from the Review (1/2): How lipid metabolism supports HCC growth and reprogramming: 🖼 Slide 1: *De novo* lipogenesis in HCC Acetate/citrate → palmitoyl-CoA → FA elongation & desaturation → fuels cancer growth and therapy resistance. #Lipogenesis #HCC 🖼

💡 New Review in @CHP_journal A deep dive into how lipid metabolic reprogramming and anti-tumor immunity intersect to drive HCC progression, resistance, and heterogeneity. HKU Pathology and HKU State Key Laboratory of Liver Research researchers — from the teams of Drs. Yu-Man

New study reveals THBS1 as a key regulator of enzalutamide resistance in prostate cancer! By combining transcriptomic & epitranscriptomic profiling, we identify potential new therapeutic targets. 🔗 https://t.co/BwAGJaT9Gf #CancerResearch #DrugResistance #m6A #Oncology

🔬 New in @CHP_journal How loss of AR activity fuels lineage plasticity in prostate cancer — @KeoViriya, @lxd2015121700, @yu_jindan & colleagues from @EmoryUniversity @emory_urology reveal a FOXA1-led TF hierarchy driving the AR cistrome. 🧠 Collapse of this network via DNA